Relationship between kalemia and intensive care unit admission or death in hospitalized COVID-19 patients: A cohort study.
COVID-19
Coronavirus
Hypokalemia
ICU
Prognosis
SARS-CoV-2
Journal
Journal de medecine vasculaire
ISSN: 2542-4513
Titre abrégé: J Med Vasc
Pays: France
ID NLM: 101709200
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
13
06
2021
accepted:
21
10
2021
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
12
4
2022
Statut:
ppublish
Résumé
SARS-CoV-2 uses Angiotensin-Converting Enzyme 2 as a viral gateway to the cell and could interact with the renin-angiotensin-aldosterone system. Other studies have shown kalemia abnormalities in patients with severe forms of coronavirus disease 2019. Our goal was to assess the prognosis value of kalemia within ten days of symptom offset in the COVID-19 hospitalized population. We analyzed data from a prospective cohort that included 65 patients with COVID-19, admitted between March 15, 2020, and March 21, 2020. The study aimed at determining the relationship between baseline kalemia and the admission to an intensive care unit (ICU) or death. The median age of the patients was 65 [54-79] years old, and 66.2% of the patients were men. Baseline kalemia under 3.8mmol/l occurred in 31 patients (48%), including 11 patients (35.5%) who were admitted to an ICU and one patient (3.2%) who died before ICU admission. In the primary end-point analysis, the adjusted hazard ratios for admission to an ICU or death were 3.52 [95% confidence interval (CI), 1.12 to 11.04] among patients with low baseline kalemia. Our study suggests that low kalemia levels within ten days of the first symptom onset might be associated with an increased risk of intensive care unit admission or death. The future perspective should be to better understand this relationship.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 uses Angiotensin-Converting Enzyme 2 as a viral gateway to the cell and could interact with the renin-angiotensin-aldosterone system. Other studies have shown kalemia abnormalities in patients with severe forms of coronavirus disease 2019. Our goal was to assess the prognosis value of kalemia within ten days of symptom offset in the COVID-19 hospitalized population.
METHODS
METHODS
We analyzed data from a prospective cohort that included 65 patients with COVID-19, admitted between March 15, 2020, and March 21, 2020. The study aimed at determining the relationship between baseline kalemia and the admission to an intensive care unit (ICU) or death.
RESULTS
RESULTS
The median age of the patients was 65 [54-79] years old, and 66.2% of the patients were men. Baseline kalemia under 3.8mmol/l occurred in 31 patients (48%), including 11 patients (35.5%) who were admitted to an ICU and one patient (3.2%) who died before ICU admission. In the primary end-point analysis, the adjusted hazard ratios for admission to an ICU or death were 3.52 [95% confidence interval (CI), 1.12 to 11.04] among patients with low baseline kalemia.
CONCLUSION
CONCLUSIONS
Our study suggests that low kalemia levels within ten days of the first symptom onset might be associated with an increased risk of intensive care unit admission or death. The future perspective should be to better understand this relationship.
Identifiants
pubmed: 35393089
pii: S2542-4513(21)00323-0
doi: 10.1016/j.jdmv.2021.10.006
pmc: PMC8557982
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-10Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Références
Angiogenesis. 2021 Aug;24(3):505-517
pubmed: 33449299
Hypertens Res. 2020 Aug;43(8):854-856
pubmed: 32439915
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Thromb Haemost. 2020 Sep;18(9):2391-2399
pubmed: 32558198
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Exp Physiol. 2008 May;93(5):543-8
pubmed: 18448662
JAMA Netw Open. 2020 Jun 1;3(6):e2011122
pubmed: 32525548
J Med Vasc. 2020 Sep;45(5):268-274
pubmed: 32862984
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Front Med (Lausanne). 2020 Nov 12;7:586307
pubmed: 33282891
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Hypertension. 1997 Sep;30(3 Pt 2):535-41
pubmed: 9322978
PLoS One. 2020 Mar 19;15(3):e0230548
pubmed: 32191764
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Stem Cell Rev Rep. 2021 Feb;17(1):4-8
pubmed: 32399806
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Angiogenesis. 2020 Nov;23(4):611-620
pubmed: 32458111
PLoS One. 2019 Mar 7;14(3):e0213096
pubmed: 30845246
Kidney Int. 2012 Mar;81(6):520-8
pubmed: 22113528
Int J Infect Dis. 2020 Nov;100:449-454
pubmed: 32950739
Arch Cardiovasc Dis. 2021 May;114(5):381-393
pubmed: 33846096